<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="3364">
  <stage>Registered</stage>
  <submitdate>27/10/2011</submitdate>
  <approvaldate>27/10/2011</approvaldate>
  <nctid>NCT01475071</nctid>
  <trial_identification>
    <studytitle>Intra-individual Comparison of Efficacy and Safety of Metvix® Natural Daylight Photodynamic Therapy Versus Conventional Metvix® Photodynamic Therapy in Subject With Mild Actinic Keratoses</studytitle>
    <scientifictitle>Intra-individual Comparison of Efficacy and Safety of Metvix® Natural Daylight Photodynamic Therapy Versus Conventional Metvix® Photodynamic Therapy in Subject With Mild Actinic Keratoses.</scientifictitle>
    <utrn />
    <trialacronym>CoMet</trialacronym>
    <secondaryid>RD.03.SPR.29102</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Actinic Keratoses</healthcondition>
    <conditioncode>
      <conditioncode1>Skin</conditioncode1>
      <conditioncode2>Dermatological conditions</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Skin</conditioncode1>
      <conditioncode2>Other skin conditions</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Metvix and natural daylight PDT
Treatment: drugs - Metvix and conventional PDT

Experimental: Metvix and daylight - 

Active Comparator: Metvix and lamp - 


Treatment: drugs: Metvix and natural daylight PDT
Methyl aminolevulinate, cream 160mg/g.One session at baseline and a second session administration at week 12 for lesions showing non-complete response and new lesions on target area.

Treatment: drugs: Metvix and conventional PDT
Methyl aminolevulinate, cream, 160mg/g. One session at baseline and a second session administration at week 12 for lesions showing non-complete response and new lesions on target area.

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Lesion Response - Percent of lesions treated at Baseline, in complete response at Week 12</outcome>
      <timepoint>Week12</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Pain Score - Subject self assessment of pain on a scale from 0 (no pain ) to 10 (extreme pain)</outcome>
      <timepoint>Baseline (during procedure), assessed after procedure</timepoint>
    </primaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1. Male or female above 18 years;

          2. Subject with clinical diagnosis of mild AK on the face or the scalp with or without
             clinical diagnosis of moderate AK on the target areas (TAs);</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1. Subject with clinical diagnosis of at least one severe AK on TAs

          2. Subject with clinical diagnosis of other skin disease (including non-melanoma skin
             cancer) on the TAs;

          3. Subject with pigmented AK on the TAs</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/03/2012</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>100</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/03/2013</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>ACT,NSW,QLD,VIC</recruitmentstate>
    <hospital>Galderma Investigational site - Phillip</hospital>
    <hospital>Galderma Investigational Site - Kogarah</hospital>
    <hospital>Galderma Investigational site - Sydney</hospital>
    <hospital>Galderma Investigational site - Westmead</hospital>
    <hospital>Galderma Investigational site - Woolloongabba</hospital>
    <hospital>Galderma Investigational site - Carlton</hospital>
    <postcode> - Phillip</postcode>
    <postcode> - Kogarah</postcode>
    <postcode> - Sydney</postcode>
    <postcode> - Westmead</postcode>
    <postcode> - Woolloongabba</postcode>
    <postcode> - Carlton</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Galderma</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The main objective of this study is to compare efficacy and safety of Metvix® natural
      daylight photodynamic therapy with those of Metvix® conventional photodynamic therapy with
      Aktilite lamp in subjects with mild actinic keratoses (intra-individual comparison).</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01475071</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Stephen Shumack</name>
      <address>St George Dermatology and skin Cancer Center</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>